Merck: VAXNEUVANCE Meets Endpoints In Phase 3 Trial Evaluating Use In Infants

Merck (MRK) said VAXNEUVANCE met key immunogenicity and safety endpoints in the PNEU-PED study in healthy infants. The Pneumococcal 15-valent Conjugate Vaccine showed a safety profile generally comparable to the licensed 13-valent pneumococcal conjugate vaccine (PCV13). At 30 days following the third dose, VAXNEUVANCE was non-inferior to PCV13 for all 13 shared serotypes.

Merck said VAXNEUVANCE also achieved key safety objectives in the phase 3 PNEU-LINK (V114-031) study in infants.

On July 16, 2021, the FDA approved VAXNEUVANCE for adults 18 years of age. The company said its plans are on track for submission of a supplemental regulatory licensure application to the FDA for use in children before the end of the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT